Furthermore, diagnostic models leveraging either TREM2 or TIMD4 as biomarkers made remarkable diagnostic accuracy in NASH, underscoring their potential clinical utility. This evidence concerns the gene TIMD4 and metabolic dysfunction-associated steatohepatitis.